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Molecular genetic analysis of five cases of 3 p -
syndrome (del(3)(qter—p25:)) was performed to
investigate the relationship between the molecular
pathology and clinical phenotype. Fluorescence in situ
hybridization studies and analysis of polymorphic DNA
markers from chromosome 3p25 - p26 demonstrated
that all four informative cases had distal deletions.
However, the extent of the deletion was variable: in two
patients with the most extensive deletions the deletion
breakpoint mapped between RAF1 and D3S1250, in one
patient the deletion breakpoint was between D3S1250
and D3S601, and in two patients the deletion
commenced telomeric to D3S601 (and telomeric to
D3S1317 in one of these). All five patients displayed
the classical features of 3 p - syndrome (mental
retardation, growth retardation, microcephaly, ptosis
and micrognathia) demonstrating that loss of
sequences centromeric to D3S1317 is not required for
expression of the characteristic 3 p - syndrome
phenotype. The three patients with the most extensive
deletions had cardiac septal defects suggesting that a
gene involved in normal cardiac development is
contained in the interval D3S1250 and D3S18. The
PMCA2 gene is contained within this region and
deletion of this gene may cause congenital heart
defects. At least three patients were deleted for the von
Hippel - Lindau (VHL) disease gene although none had
yet developed evidence of VHL disease. We conclude
that molecular analysis of 3 p - syndrome patients
enhances the management of affected patients by
identifying those at risk for VHL disease, and can be
used to elucidate the critical regions for the 3 p -
syndrome phenotype.
INTRODUCTION
Distal deletion of the short arm of chromosome 3 (3p-
syndrome) has emerged as a chromosomal disorder with a
recognizable phenotype. A total of 22 cases have been reported
and apart from one mother and son pair, all cases have arisen
de novo (1—5). Characteristic features include low birthweight,
microcephaly, trigonocephaly, hypotonia, psychomotor and
growth retardation, ptosis, telecanthus, downslanting palpebral
fissures and micrognathia. Frequent but inconstant complications
are postaxial polydactyly (nine of 22), renal anomalies (seven
of 22), cleft palate, congenital heart defects (seven of 22),
preauricular pits, sacral dimple and gastrointestinal anomalies.
The von Hippel-Lindau (VHL) disease tumour suppressor gene
maps to chromosome 3p25-p26 and patients hemizygous for
the VHL disease gene would be expected to develop VHL-related
tumours including retinal and cerebellar haemangioblastomas and
renal cell carcinoma (6). We have investigated five patients with
3 p - syndrome to define the molecular pathology of this disorder,
and to determine the relationship between the phenotypic variation
in 3p— syndrome and the extent and position of the 3p deletions.
RESULTS
Clinical studies
Case report. The previously unreported patient (CUMG3.4) was
the first child of a 26-year-old mother and an unrelated 24-year-
old father. Both parents were of Chinese origin. Pregnancy was
uneventful and the patient was born at 37 weeks gestation with
a birthweight of 2.3 kg. She was referred for investigation at
5 weeks of age because of poor feeding, inadequate weight gain
and dysmorphic features. Chromosomal analysis showed
46XX(del(3)(qter—3p25:)) and normal parental karyotypes.
Clinical findings in the proband included brachycephaly, ptosis,
telecanthus, micrognathia, bilateral preauricular sinuses" and
severe hypotonia. Echocardiography at age 4 months
demonstrated a large secundum atrial septal defect, but renal
ultrasound and skeletal survey were normal. Follow up to age
6 years has shown severe developmental delay, microcephaly (3.5
SD below mean) and growth retardation (4 SD below mean).
Summary of clinical features. Table 1 contains details of the
clinical features of the five 3 p - syndrome patients we
investigated.
Chromosome 3p deletion mapping
The results of the combined fluorescence in situ hybridization
(FISH) and molecular genetic analysis are shown in Table 2, and
the background genetic map in Figure 1. The four patients from
whom lymphoblastoid cell lines were available were investigated
by FISH analysis and each was deleted for the subtelomeric
probes D3S1442, D3S1443 and D3S1444 indicating that all had
subtelomeric deletions (see Figure 2). In one patient (CUMG3.10)
a lymphoblastoid cell line was not available so FISH analysis
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Table 1. Clinical features of five patients with 3p— syndrome investigated
Clinical features
Sex
Age (months)
Psychomotor retardation
Growth retardation
Microcephaly
Hypotonia
Ptosis
Hypertelorism/telecanthus
Preauricular pits
Micrognathia
Polydactyly
Congenital heart disease
Renal anomaly
Other
Table 2. Results
Locus
D3S651
RAF1
D3S732
D3S125O
D3S587
D3S1038
D3S601
D3S1317
D3S18
D3S1442
D3S1443
D3S1444
Patients
CUMG3.1
Male
120
+
+
+
+
+
+
+
-
Ventricular
septal defect
-
Hyperhidrosis
of deletion mapping
Patient
CUMG3.1
+
+
-
—
_
_
-
_
_
—
GM 10922
Male
13
+
+
+
+
-
-
+
-
Endocardial
cushion defect
Hypothyroidism
CUMG3.4
Female
72
+
+
+
+
+
-
+
+
-
Atrial
septal defect
-
-
in five patients with chromosome 3 p - syndrome
GM 10922
+
_
_
_
-
_
_
-
CUMG3.4
+
+
+
-
-
—
-
_
_
-
GM 10985
Female
8.5
+
+
+
+
+
-
+
-
-
+
Malrotation of the
colon, moderate
sensorineural
deafness
GM10985 CUMG3.
+
+
+
+
+
+ +
+
-
_
—
—
CUMG3.10
Female
88
+
+
+
+
-
-
+
-
-
-
Anal stenosis,
absent ear lobes,
trigonocephaly,
pectus excavatum
10
+ = not deleted, — = deleted, no entry = not done or uninformative.
was not possible and the D3S1444 microsatellite polymorphism
was uninformative. The centromeric extent of the deletions was
variable. In CUMG3.1 and GM 10922 the deletion commenced
between RAF1 and D3S1250. CUMG3.4 was retained at
D3S1250 but was deleted for more telomeric sequences. In two
patients (GM 10985 and CUMG3.10) the deletion commenced
telomeric to D3S601 (and telomeric to D3S1317 in CUMG3.10).
At least three patients (CUMG3.1, CUMG3.4 and GM10922)
were deleted for the VHL gene (see Figure 1 and Table 2).
The three patients for which parental DNA was available were
analysed using DNA polymorphisms at RAF1, D35732, D3S6O1,
D3S18, D3S1250, D3S1038, D3S1317 and D3S1444 (see Table
3). CUMG 3.10 was heterozygous at three informative loci:
D3S651, D3S1O38 and D3S1317. Although molecular genetic
analysis did not detect a chromosome 3p deletion in CUMG3.10,
cytogenetic analysis had demonstrated an unequivocal deletion
and the patient had the typical phenotypic features of 3p —
syndrome (1). CUMG3.1 and CUMG3.4 were informative at
D3S1038 and D3S18, and at D3S732 and D3S1250 respectively.
In both cases the chromosome 3p deletion detected by FISH was
confirmed and the deletion was shown to have occurred on the
maternally inherited chromosome (see Figure 3).
A possible association was detected between the extent of the
3p deletion and the occurrence of congenital heart disease in 3 p -
syndrome. The three patients with deletions extending
centromeric to D3S601 all had cardiac septal defects (ventricular
septal defect in CUMG3.1, endocardial cushion defect in
GM 10922, and an atrial septal defect in CUMG3.4). There was
no relationship between the extent of the deletion and the presence
of preauricular pits.
DISCUSSION
We have reported the clinical features of a new patient with 3 p -
syndrome, and mapped the extent of the 3p deletion in five cases
of 3p— syndrome. By using cosmid probes mapping to the
subtelomeric region of chromosome 3p we demonstrated that all
four informative patients had subtelomeric deletions; however,
Mowrey et al. (5) reported another patient (not studied by us)
with 3 p - syndrome and an interstitial deletion of chromosome
3p25—p26. The centromeric extent of the chromosome 3p
deletions were variable: in two patients the deletion commenced
between RAF1 and D3S1250, in one between D3S1250 and
D3S587, and in two patients the deletion breakpoint was telomeric
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Figure 1. Map of chromosome 3p25—p26. The location of the four deletion breakpoints for which flanking markers were demonstrated are shown. The breakpoint
in CUMG3.10 was telomeric to D3S1317, but this case was not informative at more telomeric loci.
Table 3. Details of FISH probes and polymorphic markers investigated
Locus
D3S651
RAFl
D3S732
D3S1250
D3S587
D3S1038
D3S601
D3S1317
D3S18
D3S1444
D3S1442
D3S1443
Fish probe
CI3-312
CRcl29
LIB 4A-52
cos 56
cLIB 12-48
-
cos 7
-
cLIB-1
3PT-B47-2G
3PT-B47-5E
3PT-B47-2A
Polymorphism
Microsatellite
Taq\
HindUl
-
EcoRl
Microsatellite
Taql
Microsatellite
BamHl
Microsatellite
-
-
Reference
(22)
(11)
(U)
(12)
(16)
(13)
(11)
(14)
(11)
Dietz-Band unpublished observations
Dietz-Band unpublished observations
Dietz-Band unpublished observations
- = not investigated or not available
to D3S601 (and telomeric to D3S1317 in one of these). Mowrey
etal. (5) had mapped the deletion breakpoints in GM10922 and
GM10985 between RAFl and D3S18, and we were able to
sublocalize the deletion endpoints within this interval, and
demonstrate that the deletions were different in the two patients.
In addition to the five patients with 3p— syndrome, we have also
mapped the chromosome 3p breakpoint in seven patients with
inversions or translocations involving chromosome 3p25-p26
(8; unpublished observations). In two cases the translocation or
inversion breakpoint mapped between RAFl and D3S1250,
between D3S1250 and D3S601 in one case; between D3S601
and D3S18 in two cases, and telomeric to D3S18 in two cases.
The approximate genetic distance between RAFl and D3S1250
is 2 cM, between D3S1250 and D3S601 is 2 cM, and between
D3S601 and D3S18 is 2 cM (see Figure 1). Thus the distribution
of cytogenetic breakpoints within the RAFl to D3S18 interval
is approximately proportional to the genetic distances between
loci and does not provide evidence for a 'hot spot' for cytogenetic
rearrangements within a specific subinterval.
The parental origin of de novo 3p deletions was defined in two
cases, and was maternal in both cases. In a further three cases
of de novo 3 p - syndrome studied by Mowrey et al. (5), the
deletion was of paternal origin in two cases and maternal in one.
Genomic imprinting of genes within chromosome 3p25— p26 has
not been reported and we were unable to discern any effect of
the parent of origin of the 3p deletion on the clinical phenotype.
In 4 p - and 5 p - syndromes (Wolf-Hirschhom and cri-du-chat
syndromes respectively), 80% of de novo deletions arise in the
paternal germline (reviewed in reference 19). Further
investigations are required to determine whether the differences
in the parental origin of 3 p - , 4 p - and 5 p - syndrome patients
is a real finding or reflects the small number of 3p cases in which
the parental origin has been defined.
All five patients investigated displayed typical features of 3p—
syndrome, so it appears that the classical features of 3 p -
syndrome (psychomotor and growth retardation, dysmor-
phological features) result from loss of genes telomeric to
D3S1317. Mowrey et al. (5) reported that a patient with an
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Figure 2. FISH studies in four patients with 3 p - syndrome. In each case there is a hybridization signal from the normal chromosome 3pter but not from the deleted
homologue. (a) CUMG3.1 and D3S1442, (b) GM10922 and D3S1443, (c) GM10985 and D3S1442, (d) CUMG3.4 and D3S1442.
interstitial deletion of chromosome 3p25-p26 between RAF1
and D3S17 (which maps 19 cM telomeric to D3S18) displayed
typical features of 3p— syndrome. Thus the critical region for
the expression of classical 3p— syndrome appears to be a 21 cM
interval between D3S1317 and D3S17 (see Figure 1). An
intriguing finding was the possible relationship between the extent
of the 3p deletion and the presence of congenital heart disease
in 3 p - syndrome. If the observed association between cardiac
septal defects and more extensive 3p deletions is causal, then a
gene involved in normal cardiac development should be contained
between D3S1250 and D3S18. Three genes have been isolated
from this region: (i) plasma membrane calcium transporting
ATPase isoform 2 gene (PMCA2) (16); (ii) g6 a cDNA of
unknown function; and (iii) the VHL disease gene (6). VHL
disease patients with large germline deletions including both the
VHL gene and g6 do not have congenital heart disease (6), but
the PMCA2 gene (which is not deleted in these patients) may
be a candidate gene for the occurrence of cardiac septal defects
in 3p— syndrome.
Although VHL disease has not been reported in 3 p - syndrome
patients, the VHL gene was deleted in a least three of five cases
we investigated. The absence of VHL disease in these patients
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Figure 3. Maternal origin of distal 3p deletion in two patients with 3 p - syndrome.
For CUMG3.1 the affected child (C) has failed to inherit the Al allele at D3S1250
from the mother (M), but has inherited A2 allele from the father (F). For
CUMG3.4 the affected child (C) has failed to inherit the A2 allele at D3S18 from
the mother (M), but has inherited A2 allele from the father (F). (c = constant band).
reflects the young age of the children investigated (the penetrance
of VHL disease is 0.05 at 10 years; 20). Early detection of retinal
angiomatosis and renal cell carcinoma in VHL disease patients
reduces morbidity and mortality (21). Therefore 3 p - syndrome
patients found to be deleted for the VHL gene should be screened
for evidence of VHL complications with an appropriate screening
programme (20). Further molecular investigations will identify
the minimal deletion necessary for expression of the 3 p -
syndrome and provide further information on the relationship
between the molecular pathology and the clinical phenotype.
PATIENTS AND METHODS
Patients
Five patients with cytogenetic deletions of chromosome 3p25-p26
(del(3)(qter—p25:)) and normal parental chromosomes were investigated. The
clinical features of four patients have been reported in detail previously: CUMG3.1
(7), CUMG3.10 (1), GM10985 and GM10922 (cases 1 and 2 respectively in
reference 3). For these patients a summary of the clinical features was prepared
from the published reports and updated by re-examination of the affected child
in two cases (CUMG3.1 and CUMG3.10). Lymphoblastoid cell lines were
available from four patients (CUMG3.1, CUMG3.4, GM10985 and GM10922)
and DNA from the affected child and both parents in three families (CUMG3.1,
CUMG3.4 and CUMG3.10). Lymphoblastoid cell lines for cases GM10985 and
GM 10922 were obtained from the NIGMS Genetic Mutant CeU Repository,
Camden, New Jersey, USA.
FISH analysis
Molecular cytogenetic studies were performed by FISH on metaphase chromosome
spreads prepared from EBV transformed cell lines as described previously (8).
Cosmid probes were biotinylated by nick translation with biotin-11-dUTP (Sigma).
Chromosomal in situ suppression (CISS) hybridization was performed to improve
the specificity of hybridization with unlabelled sheared human placenta! DNA
added to the biotin-labelled probe at a ratio of 50-100:1. Hybridization signals
were visualized by two-layer avidin fluorescein isothiocyanate (FTTC) detection
system (9) and analysis was carried out under a confocal laser scanning microscope
(MRC 600; Bio-Rad Microscience Ltd) with a lOOxPlan Apo objective lens
(Nikon) and a Nikon Optophot fluorescence microscope. The images were
photographed using Kodacolor Gold film.
Metaphase spreads were investigated with cosmid probes at RAF1, D3S651,
D3S1250, D3S587, D3S601, D3S18, D3S1442, D3S1443 and D3S1444 (see Table
3). The three cosmid probes for D3S1442, D3S1443 and D3S1444 detect
chromosome 3p-specific subtelomeric sequences (10; Dietz-Band unpublished
observations). The results of FISH analyses for cases CUMG3.1 and CUMG3.4
at RAF1, D3S651, D3S732, D3S1250, D3S587, D3S601 and D3S18 were
included in a previous physical mapping paper (8), and Mowrey et al. (5) have
previously studied GM10922 and GM1O985 at RAF1, D3S18 and D3S17.
Molecular genetic studies -
DNA was available from the parents of CUMG3.1, CUMG3.4 and CUMG3.10.
These families were analysed using restriction fragment length polymorphisms
or microsatellite polymorphisms at RAF1, D35732, D3S601, D3S18 (11),
D3S1250 (12), D3S1038 (13), D3S1317 (14) and D3S1444 (Dietz-Band in
preparation; see Table 3) to confirm the results of FISH analysis and to establish
the parent of origin of the chromosome 3p deletions.
Background map
The order of loci in chromosome 3p25 -p26 is shown in Figure 1, and was derived
from a variety of studies (6,11,12,15-18).
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